Quinoline type mevalonolactones

• US 5,856,336 A
• Filed: 05/15/1992
• Issued: 01/05/1999
• Est. Priority Date: 08/20/1987
• Status: Expired due to Term

• Current Assignee: Nissan Chemical Corporation
• Original Assignee: Nissan Chemical Industries Limited (Shin-Etsu Chemical Company Limited)
• Inventors: Iwasaki, Hiroshi, Fujikawa, Yoshihiro, Suzuki, Mikio, Kitahara, Masaki, Sakashita, Mitsuaki
• Primary Examiner(s): STOCKTON, LAURA LYNNE
• Application Number:
  US07/883,398
• Time in Patent Office: 2,426 Days
• Field of Search: 546/173, 514/311
• US Class Current: 514/311
• CPC Class Codes: A61P 3/06 Antihyperlipidemics
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C07D 215/14 Radicals substituted by oxygen atoms
• CPC Class Codes: C07D 215/18 Halogen atoms or nitro radicals
• CPC Class Codes: C07D 215/20 Oxygen atoms
• CPC Class Codes: C07D 405/06 linked by a carbon chain containing only aliphatic carbon atoms

Abstract

A compound of the formula ##STR1## Z=--CH(OH)--CH₂ --CH(OH)--CH₂ --COO.1/2Ca have HMG--CoA inhibiting effects, making them useful as inhibitors of cholesterol biosynthesis. The compound may be prepared as a pharmaceutical for reducing hyperlipidemia, hyperlipoproteinemia or atherosclerosis.

Claims

1. A compound of the formula, ##STR16## Z=--CH(OH)--CH₂ --CH(OH)--CH₂ --COO.1/2Ca.

2. A method for reducing hyperlipidemia, hyperlipoproteinemia or atherosclerosis, which comprises administering an effective amount of the compound of formula A as defined in claim 1.